Louis Gall

Louis Gall

Auto-generated profile, based on publicly available information

Louis Gall

Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2025 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
CGChristopher E. Goldring
Christopher E. Goldring
GRGiusy Russomanno
Giusy Russomanno
CPCarmen Pin
Carmen Pin
PTPanuwat Trairatphisan
Panuwat Trairatphisan
KBKylie A. Beattie
Kylie A. Beattie
LLLoic Laplanche
Loic Laplanche

8 December 2023 in eLife
Verified
Journal Article
Open access
LGLouis Gall
Louis Gall
CDCarrie Duckworth
Carrie Duckworth
FJFerran Jardi
Ferran Jardi
LLLieve Lammens
Lieve Lammens
APAimee Parker
Aimee Parker
CPCarmen Pin
Carmen Pin
The maintenance of the functional integrity of the intestinal epithelium requires a tight coordination between cell production, migration, and shedding along the crypt–villus axis. Dysregulation of these processes may result in loss of the intestinal barrier and disease. With the aim of generating a more complete and integrated understanding of how the epithelium maintains homeostasis and recovers after injury, we have built a multi-scale agent-based model (ABM) of the mouse intestinal epithelium. We demonstrate that stable, self-organizing behaviour in the crypt emerges from the dynamic interaction of multiple signalling pathways, such as Wnt, Notch, BMP, ZNRF3/RNF43, and YAP-Hippo pathways, which regulate proliferation and differentiation, respond to environmental mechanical cues, form feedback mechanisms, and modulate the dynamics of the cell cycle protein network. The model recapitulates the crypt phenotype reported after persistent stem cell ablation and after the inhibition of the CDK1 cycle protein. Moreover, we simulated 5-fluorouracil (5-FU)-induced toxicity at multiple scales starting from DNA and RNA damage, which disrupts the cell cycle, cell signalling, proliferation, differentiation, and migration and leads to loss of barrier integrity. During recovery, our in silico crypt regenerates its structure in a self-organizing, dynamic fashion driven by dedifferentiation and enhanced by negative feedback loops. Thus, the model enables the simulation of xenobiotic-, in particular chemotherapy-, induced mechanisms of intestinal toxicity and epithelial recovery. Overall, we present a systems model able to simulate the disruption of molecular events and its impact across multiple levels of epithelial organization and demonstrate its application to epithelial research and drug development.

11 September 2023 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
LGLouis Gall
Louis Gall
FJFerran Jardi
Ferran Jardi
LLLieve Lammens
Lieve Lammens
JPJanet Piñero
Janet Piñero
TSTerezinha M. Souza
Terezinha M. Souza
CPCarmen Pin
Carmen Pin
We have built a quantitative systems toxicology modeling framework focused on the early prediction of oncotherapeutic‐induced clinical intestinal adverse effects. The model describes stem and progenitor cell dynamics in the small intestinal epithelium and integrates heterogeneous epithelial‐related processes, such as transcriptional profiles, citrulline kinetics, and probability of diarrhea. We fitted a mouse‐specific version of the model to quantify doxorubicin and 5‐fluorouracil (5‐FU)‐induced toxicity, which included pharmacokinetics and 5‐FU metabolism and assumed that both drugs led to cell cycle arrest and apoptosis in stem cells and proliferative progenitors. The model successfully recapitulated observations in mice regarding dose‐dependent disruption of proliferation which could lead to villus shortening, decrease of circulating citrulline, increased diarrhea risk, and transcriptional induction of the p53 pathway. Using a human‐specific epithelial model, we translated the cytotoxic activity of doxorubicin and 5‐FU quantified in mice into human intestinal injury and predicted with accuracy clinical diarrhea incidence. However, for gefitinib, a specific‐molecularly targeted therapy, the mice failed to reproduce epithelial toxicity at exposures much higher than those associated with clinical diarrhea. This indicates that, regardless of the translational modeling approach, preclinical experimental settings have to be suitable to quantify drug‐induced clinical toxicity with precision at the structural scale of the model. Our work demonstrates the usefulness of translational models at early stages of the drug development pipeline to predict clinical toxicity and highlights the importance of understanding cross‐settings differences in toxicity when building these approaches.

26 October 2023 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
AUAydar Uatay
Aydar Uatay
LGLouis Gall
Louis Gall
LILinda Irons
Linda Irons
STShivendra G. Tewari
Shivendra G. Tewari
XZXu (Sue) Zhu
Xu (Sue) Zhu
HKHolly Kimko
Holly Kimko

26 October 2021 in Journal of High Energy Physics
Verified
Journal Article
Open access
PDF file
LGL. Gall
L. Gall
TMT. Mohaupt
T. Mohaupt
String theory, specifically type-II superstring theory, can be formulated in any ten-dimensional signature. To facilitate the study of supergravity and superstring theories in this setting, we present a uniform construction of supersymmetry algebras in arbitrary dimension and signature, which generalizes the ideas underlying symplectic Majorana spinors. In our formalism R-symmetry acts on an auxiliary multiplicity space which makes its action manifest. This allows us to provide extensive tables which list the R-symmetry groups of extended supersymmetry algebras for all signatures together with other useful information. Twisted (‘type-*’) supersymmetry algebras in Lorentz signature with non-compact R-symmetry groups are shown to be part of a general pattern resulting from the interplay between complex superbrackets and reality conditions. As an application we show how the relations between type-II string theories in ten and nine dimensions can be extracted from their supersymmetry algebras. We also use our results to determine the special geometry of vector and hypermultiplet scalar manifolds of four-dimensional $$ \mathcal{N} $$N = 2 and three-dimensional $$ \mathcal{N} $$N = 4 supergravity theories for all signatures.

25 April 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
CPCarmen Pin
Carmen Pin
DMDeepa Maheshvare M.
Deepa Maheshvare M.
LGLouis Gall
Louis Gall
AHAndrew Hall
Andrew Hall
MCMuireann Coen
Muireann Coen
KPKenneth Pryde
Kenneth Pryde
Gastrointestinal (GI) toxicity is a common and potentially severe side effect of antiproliferative cancer therapies that often requires dose reduction or treatment interruption. Despite the clinical implications, there are currently no robust strategies for quantitative preclinical assessment of GI toxicity. We have developed a human small intestinal organoid (hSIO)‐based mathematical modeling approach for the early prediction of GI toxicity of oral antiproliferative cancer treatments. Our approach integrates the exposure‐toxicity relationship quantified in hSIOs into a human mathematical model of the epithelium that enables the simulation of the impact of crypt proliferation impairment on epithelial dynamics. We show that, for oral drugs, when the enterocyte free drug concentration is used as a surrogate for the crypt exposure, the extent of the epithelial injury correlates with reported clinical incidence and severity of diarrhea. In contrast, when relying on plasma exposure, the model failed to predict intestinal injury for two out of the six diarrheagenic drugs tested. Our modeling approach distinguished the toxicity profiles of CDK4/6 inhibitors, predicting minimal epithelial injury for ribociclib and substantial epithelial disruption for abemaciclib, consistent with its higher clinical incidence of diarrhea. Similarly, the toxicity quantified in hSIOs enabled accurate prediction of epithelial injury and diarrhea severity for four epithelial growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). This approach introduces new GI safety assessment and clinical dose selection paradigms to enable the simulation of patients' response based upon in vitro drug response modeling.